For example, upregulation of S100A11 [65,110] and S100A8 [111] expression was observed in the liver of NAFLD patients and various mouse models of obesity and/or steatosis, as well as in hepatocytes exposed to fatty acids, thus suggesting a strong implication of these two S100 isoforms in NAFLD development [65,110,112]. This evidence concerns the gene S100A11 and metabolic dysfunction-associated steatotic liver disease.